Linical

Synthon | May 18, 2016

Synthon Biopharmaceuticals (‘Synthon’) today announced the initiation of the second part of its ongoing Phase I clinical trial with the investigational anti-HER2 antibody-drug conjugate (ADC) SYD985. The second part will see 48 additional heavily pre-treated patients with HER2-positive breast cancer enrolled into the SYD985.001 trial. This marks an important next step in the development of SYD985, the frontrunner of Synthon’s duocarmycin-based ADC platform....

Teva Pharmaceuticals | October 17, 2016

JERUSALEM & TARRYTOWN, N.Y.--(BUSINESS WIRE)--Oct. 17, 2016-- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) today provided an update on fasinumab, triggered by a recent development in a Phase 2b fasinumab study in patients with chronic low back pain....

Pharama | December 25, 2016

On Friday, the pharmaceutical society’s president Paul Mwaniki, (below), while saying his union would stop issuing drugs, said the medicines they issue are “handled by people who are not competent”....

BioSpace (a DHI Group, Inc. company) | January 18, 2017

New York City and Princeton, NJ-based Ophthotech Corporation (OPHT) has announced that it is cutting about 80 percent of its staff in the first six months of this year. On December 12, 2016, the company announced that its two pivotal Phase III clinical trials evaluating Fovista (pegpleranib) anti-PDGF therapy in combination with Lucentis (ranibizumab) compared to Roche (RHHBY)’s Lucentis monotherapy for wet age-related macular degeneration (AMD) failed to hit their primary endpoints. The pre...